Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel

• Published in: European urology oncology Vol. 5; no. 1; pp. 18 - 29
• Main Authors: Mahal, Brandon A., Gerke, Travis, Awasthi, Shivanshu, Soule, Howard R., Simons, Jonathan W., Miyahira, Andrea, Halabi, Susan, George, Daniel, Platz, Elizabeth A., Mucci, Lorelei, Yamoah, Kosj
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-02-2022
• Subjects: Disease Progression; Epidemiology; Humans; Incidence; Male; Prostate cancer; Prostatic Neoplasms - pathology; Race disparities; Socioeconomic Factors; Prostate cancer; Epidemiology; Race disparities
• ISSN: 2588-9311; 2588-9311
• DOI: 10.1016/j.euo.2021.07.006

Prostate cancer (PCa) is a complex disease that disproportionately impacts Black men in the USA. The structural factors that drive heterogeneous outcomes for patients of differing backgrounds are probably the same ones that result in population-level disparities. The relative contribution of drivers along the PCa disease continuum is an active area of investigation and debate.
To critically synthesize the available evidence on PCa disparities from a population-level perspective in comparison to data from “equal access and equal care settings” and to provide a consensus summary of the state of PCa disparities.
A plenary panel on PCa disparities presented at the Prostate Cancer Foundation meeting on October 24, 2019 and ensuing discussions are reported here. We used a systematic literature review approach and the Preferred Reporting Items for Systematic Reviews and Meta-analyses to select the most relevant publications. A total of 3333 publications between 2011 and 2021 were retrieved, of which 52 were included in the review; an additional 13 articles on screening guidelines, seminal clinical trials, and statistical methodology were used in the evidence synthesis.
Race disparities in PCa are a result of a complex interaction between socioeconomic factors impacting access to care and ancestral/genetic factors that may influence tumor biology. Black men in the USA continue to have a nearly 1.8 times higher population-level incidence rate than White men. Failure to account for the race-specific incidence burden would continue to lead to residual disparity even after achieving relatively similar outcomes after primary treatment, resulting in a higher long-term mortality burden. Selection bias remains possible in PCa studies, which often rely on highly specific cohorts of Black men with higher use of health care resources that may not represent the average Black patient in the USA. Novel methods including mediation analysis and genetic ancestry rather than self-identified race can optimize analytical models investigating racial disparities and may lead to a better understanding of PCa genomic diversity and behavior.
Our findings emphasize the importance of racially diverse studies, including precision -omics, prevention, and targeted therapy initiatives, to elucidate mechanisms underlying racial differences in outcomes and response to therapy. We propose novel approaches for studying and addressing PCa disparities. Contemporary methods, particularly in the domain of mediation analysis, can promote scientific rigor in understanding these disparities.
Inaccurate data interpretation or lack of data altogether for Black men can impact policy and ultimately affect millions of individuals of African origin worldwide. Our review identifies a need to develop and prioritize a strategy for including Black and other men with prostate cancer in intervention studies and randomized clinical trials to halt the widening prostate cancer disparities.
Inaccurate data interpretation or lack of data altogether for Black men can impact policy, potentially in a detrimental way, ultimately affecting millions of individuals of African origin worldwide. In this report we identified the need to develop and prioritize a strategy for including Black and other minority men with prostate cancer in intervention studies and randomized clinical trials to avert the widening gap for prostate cancer disparities in the era of personalized medicine.